Helio Genomics is a LiverRight partner and had big news on March 18, 2026:
Helio Genomics to Make HelioLiver™ Cancer Test Accessible to Quest Diagnostics’ Providers
“Quest’s Infrastructure to Enable Access to HelioLiver™, an AI-Powered, Blood-Based Test for Early Detection of Liver Cancer”
What happened
- Helio Genomics partnered with Quest Diagnostics to expand access to its HelioLiver blood test for liver cancer detection.
- Starting April 2026, any provider with a Quest account can order it.
What the test is
- A blood-based test for early detection of liver cancer (HCC)
- Uses:
- Cell-free DNA methylation
- Protein biomarkers
- Patient demographics
- AI algorithm
👉 Goal: detect cancer earlier than imaging alone
Why this matters
- Liver cancer is rising fast:
- Incidence ↑ ~3x, mortality ↑ ~2x
- 80–90% of at-risk patients don’t get screened today
👉 Big gap = poor outcomes
Key advantage
- Fits into routine care with a simple blood draw
- Can detect signals even when ultrasound is inconclusive
👉 This is all about: Access + Adherence + Earlier Detection
Prediction
Blood-based liver cancer screening is moving toward mainstream clinical adoption at scale.